Scientific Library
- Acute Coronary Syndrom
- ASCVD Prevention
- Bifurcation Stenting
- Cardio-Oncology
- Congestive Heart Failure
- DAPT Duration
- Drug Coated Balloon
- Fractional Flow Reserve
- IVUS Guidance
- Optical Coherence Tomography
- Pulmonary Hypertension
- Rotational Atherectomy
- Shear Stress
- Stenting Left Main
- Transcatheter Aortic Valve Replacement
- Percutaneous LAA Occlusion
- Mitral/Tricuspid Valvular Disease
- Other Relevant Articles
-
Longitudinal Change in Galectin-3 and Incident Cardiovascular OutcomesA Ghorbani, V Bhambhani, RH Christenson et al. -
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-ReducedF Zannad, JP Ferreira, SJ Pocock et al.
-
Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-DefibrillatorsBilchick KC, Wang Y, Cheng A et al.
-
Positive recommendation for angiotensin receptor/neprilysin inhibitor: First medication approval for heart failure without "reduced ejection fraction"JG Howlett.
-
Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist SystemsBerg DD, Vaduganathan M, Stewart GC et al.
-
Dapagliflozin for treating chronic heart failure with reduced ejection fractionNational Institue for Health and Care Excellence
-
The Management of Atrial Fibrillation in Heart Failure: An Expert Panel ConsensusD Farmakis, C Chrysohoou, G Giamouzis et al.
-
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced TrialSD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
